WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314247

CAS#: 164650-44-6

Description: Efinaconazole is a triazole antifungal. It is approved for use in Canada and the USA as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail). Efinaconazole acts as a 14α-demethylase inhibitor. Efinaconazole inhibits fungal lanosterol 14α-demethylase involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes. Efinaconazole has been shown to be active against isolates of the following microorganisms, both in vitro and in clinical infections. Efinaconazole exhibits in vitro minimum inhibitory concentrations (MICs) of 0.06 μg/mL or less against most ( ≥ 90%) isolates of the following microorganisms: Trichophyton rubrum; Trichophyton mentagrophytes.

Chemical Structure

CAS# 164650-44-6

Theoretical Analysis

MedKoo Cat#: 314247
Name: Efinaconazole
CAS#: 164650-44-6
Chemical Formula: C18H22F2N4O
Exact Mass: 348.1762
Molecular Weight: 348.39
Elemental Analysis: C, 62.05; H, 6.36; F, 10.91; N, 16.08; O, 4.59

Price and Availability

Size Price Availability Quantity
50.0mg USD 150.0 Ready to ship
100.0mg USD 250.0 Ready to ship
200.0mg USD 450.0 Ready to ship
500.0mg USD 950.0 Ready to ship
1.0g USD 1650.0 Ready to ship
2.0g USD 2450.0 Ready to ship
5.0g USD 4250.0 Ready to ship
10.0g USD 5650.0 Ready to ship
Click to view more sizes and prices
Bulk inquiry

Synonym: KP103; KP-103; KP 103; CTK5J2975; AGJ95634; KB145948; Efinaconazole; trade name: Jublia.

IUPAC/Chemical Name: (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol


InChi Code: InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1

SMILES Code: C[C@@H](N1CCC(CC1)=C)[C@@](O)(C2=CC=C(F)C=C2F)CN3N=CN=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 348.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Pollak RA. Efinaconazole topical solution, 10% the development of a new topical treatment for toenail onychomycosis. J Am Podiatr Med Assoc. 2014 Nov;104(6):568-73. doi: 10.7547/8750-7315-104.6.568. PubMed PMID: 25514267.

2: Tosti A, Elewski BE. Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life. J Clin Aesthet Dermatol. 2014 Nov;7(11):25-30. PubMed PMID: 25489379; PubMed Central PMCID: PMC4255695.

3: Gupta AK, Simpson FC, Abramovits W, Scheinfeld N. Efinaconazole 10% nail solution: a post-FDA approval update. Skinmed. 2014 Jul-Aug;12(4):235-7. PubMed PMID: 25335353.

4: Zeichner JA, Stein Gold L, Korotzer A. Penetration of ((14)C)-Efinaconazole Topical Solution, 10%, Does Not Appear to be Influenced by Nail Polish. J Clin Aesthet Dermatol. 2014 Sep;7(9):34-6. PubMed PMID: 25276275; PubMed Central PMCID: PMC4174918.

5: Joseph WS, Vlahovic TC, Pillai R, Olin JT. Efinaconazole 10% solution in the treatment of onychomycosis of the toenails. J Am Podiatr Med Assoc. 2014 Sep-Oct;104(5):479-85. doi: 10.7547/0003-0538-104.5.479. PubMed PMID: 25275736.

6: Efinaconazole topical solution (Jublia) for onychomycosis. Med Lett Drugs Ther. 2014 Sep 15;56(1451):88-9. PubMed PMID: 25211303.

7: Jo W, Glynn M, Nejishima H, Sanada H, Minowa K, Calvarese B, Senda H, Pillai R, Mutter L. Nonclinical safety assessment of Efinaconazole Solution (10%) for onychomycosis treatment. Regul Toxicol Pharmacol. 2014 Oct;70(1):242-53. doi: 10.1016/j.yrtph.2014.07.012. Epub 2014 Jul 16. PubMed PMID: 25038564.

8: Gupta AK, Elewski BE, Sugarman JL, Ieda C, Kawabata H, Kang R, Pillai R, Olin JT, Watanabe S. The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials. J Drugs Dermatol. 2014 Jul;13(7):815-20. PubMed PMID: 25007364.

9: Iwata A, Watanabe Y, Kumagai N, Katafuchi-Nagashima M, Sugiura K, Pillai R, Tatsumi Y. In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal. Antimicrob Agents Chemother. 2014 Aug;58(8):4920-2. doi: 10.1128/AAC.02703-13. Epub 2014 May 27. PubMed PMID: 24867968; PubMed Central PMCID: PMC4136074.

10: Gupta AK, Simpson FC. Efinaconazole (Jublia) for the treatment of onychomycosis. Expert Rev Anti Infect Ther. 2014 Jul;12(7):743-52. doi: 10.1586/14787210.2014.919852. Epub 2014 May 22. PubMed PMID: 24850511.